Regulates IgE Overproduction

AllergX® rebalances an immune system imbalance that results in overproduction of Immunoglobulin E (IgE). Too much IgE results in a hypersensitive release of histamine which triggers the allergic response.*

Maintains Healthy Nasal Function

AllergX® helps maintain healthy nasal function throughout the pollen season.*

Clinically Shown As Effective

Clinical studies in the USA on over 2,500 subjects have shown that AllergX® is 100% free from drowsy and sedating side effects.*

"Allergies are NOT normal. By regulating the over-production of IgE Antibodies naturally, AllergX® helps restore your body’s normal response to seasonal and year-round allergens, which is NO ALLERGIC RESPONSE AT ALL!"

Dr. Paul H. Ratner, MD
Board Certified Allergist


AllergX® Science

Approximately $10,000,000 was spent on clinical studies.

An Exposure Scientific-associated company sponsored a series of studies in California by allergists using cobalamins in a formula developed by the original inventor, Ernest T. Armstrong. In 1991, Richard D. O’Connor, M.D., Clinical Professor Immunology and Allergy, University of California, San Diego School of Medicine, presented the results at an FDA meeting. Chris Nardo, Ph.D., a North Carolina University biostatistician, computed significant Wilcoxon-Rank of .002 for nasal function; and p = .005 for IgE reductions.

Lyndon Mansfield, M.D., Board Certified in Allergy and Immunology, was investigator for a 1992 double-blind, placebo-controlled study on humans in Texas. Subjects received 15 days of cobalamin (62 subjects), or placebo (67 subjects). Total serum IgE was measured pre-trial and post-trial. A T-test showed a significant change in mean total serum IgE levels (p=0.0379) for the cobalamin group at Day 30 compared to Day 0 while the placebo group did not (p=0.1268). Total nasal function scores strongly favored the cobalamin group, with statistical significance at Week 3 (p=0.02).

Chart 1:
Placebo-Controlled Study Change in IgE Levels

Click Chart To Enlarge

The inventor of AllergX®, Ernest Armstrong, directed a double-blind, placebo-controlled study on cobalamin in the Pacific Northwest, USA during pollen and mold season.

On August 14, 1996 Dr. Lyndon Mansfield presented the results to FDA’s Pulmonary and Allergy Division, including its then-Director, Dr. John Jenkins. The following chart shows the results of cobalamin administration over placebo over a 10-week period on 42 people.

Chart 2:
Nasal Function in Pollen and Mold Season

Click Chart To Enlarge

In 2000, a Japanese study was conducted by Dr. Funada on groups of mice.

Some were administered cobalamins while others were not.

After administration, IgE and histamine concentrations were significantly lower in all cobalamin-administered groups vs. controls.

Chart 3:
Cobalmins Reduce Mouse Levels of IgE and Histamine

Click Chart To Enlarge

In 2006, the inventor of AllergX®, Ernest Armstrong, directed a double-blind, placebo-controlled, parallel group study on AllergX. The study was done on 1,551 human subjects by Board Certified Allergists at 23 sites in 13 eastern U.S. states and Texas during the ragweed pollen season.

METHODS: Each subject had three visits to the clinic. At Visit 1 (before the trial) and Visit 3 (after the trial), they underwent a physical exam, and had blood and urine samples collected for laboratory analyses.  The blood samples were analyzed for IgE and cobalamin levels. CBC and chemistry panels were run for safety analyses.  Every day during the six-week study, the subjects self-rated their nasal function in the morning and in the evening by entering a numeric score on the keypad of a telephone or via a computer connected to a secure Internet database. Subjects took the main ingredient in AllergX or a placebo (“sugar pill”) daily in the morning and evening.

RESULTS: 2006 was an exceptionally mild ragweed pollen season.

There was almost a 300% increase in cobalamin levels in the active group and essentially no change in the placebo group.  The average Immunoglobulin E antibody (IgE) level for the 737 active subjects increased from 6.27 (pre-pollen season) to 7.68 (post-pollen season) (increase of 1.41), while the average for the 735 placebo subjects increased from 6.34 to 9.20 (increase of 2.86). IgE levels generally increase during the allergy season.  AllergX blunted this expected seasonal rise in IgE.

Chart 4:
Change in Nasal Function in Pollen Season

Click Chart To Enlarge

Compare Allergy Symptoms Reported By The Group That Received Placebo Versus The Group That Received The Active Ingredient in AllergX™.

NOTE: Lower scores reflect fewer allergy symptoms.


View US Patent!





*These statements have not been evaluated by the Food & Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Always seek professional medical attention for any medical concerns you may have. If this is an emergency, call 911 or go to your nearest emergency room. The information on this website is not intended as medical advice or to replace the advice of a qualified medical professional.